Healthcare / Diagnostics & ResearchNasdaqCM
$1.71
+0.11 (+6.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-8.0M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
2.6x
↓EV/EBITDA
2.4x
↓ROE
120.5%
↑Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $4.1M · FCF $-46000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $4.1M | $4.1M | $-25.1M | $-17.6M | $-19.1M |
| EBITDA | $4.4M | $4.4M | $-25.0M | $-17.3M | $-18.7M |
| EPS | 0.66 | 0.66 | -4.30 | -3.00 | -3.37 |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | -0.09 | — | 0.02 |
| Current Ratio | 0.05 | 0.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-46000.00 | $-46000.00 | $-8.0M | $-17.0M | $-19.2M |
| Returns | |||||
| ROE | 120.5% | 120.5% | 1734.4% | -74.2% | -46.3% |
| Valuation | |||||
| P/E | 2.59 | 2.59 | — | — | — |
| EV/EBITDA | 2.45 | 2.45 | — | — | — |
| P/B | 3.10 | 3.10 | — | 0.51 | 0.37 |
| Growth & Yield | |||||
| EPS Growth | 115.3% | 115.3% | -43.3% | 11.0% | — |
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-38.7%
EPS terminal req.
$0.15
Spread vs growth
154.1%
5Y implied EPS CAGR
-22.6%
EPS terminal req.
$0.18
Spread vs growth
137.9%
10Y implied EPS CAGR
-7.7%
EPS terminal req.
$0.30
Spread vs growth
123.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+109.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.30 → 0.66
Residual
+109.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.